Sanxin Medtec(SZ:300453) Zheng Quan Zhi Xing·2025-08-08 12:13Core Viewpoint - The legal opinion letter from Jiangxi Huabang Law Firm confirms that Jiangxi Sanxin Medical Technology Co., Ltd. has fulfilled the necessary conditions for the first unlock period of its 2024 restricted stock incentive plan, including adjustments to the repurchase price and the repurchase and cancellation of certain restricted stocks [1][7][21] Group 1: Approval and Authorization - The company has obtained necessary approvals and authorizations for the first unlock period of the incentive plan, including the verification of the list of incentive recipients by the supervisory board [6][14] - The first unlock period for the restricted stocks begins 12 months after the completion of the stock grant registration [8][14] Group 2: Conditions for Unlocking - The conditions for unlocking the restricted stocks have been met, as the company did not receive any negative audit opinions or fail to distribute profits according to regulations [8][9][14] - The company achieved a revenue growth rate of at least 15% and a net profit growth rate of at least 10% compared to the previous year, fulfilling the performance targets set in the incentive plan [10][12][14] Group 3: Repurchase and Cancellation of Stocks - A total of 31.325 million shares of restricted stocks will be repurchased and canceled due to two incentive recipients leaving the company and 29 recipients not meeting the personal performance criteria [17][20] - The repurchase price for the restricted stocks is subject to adjustment based on the company's profit distribution plans, with the current price set at 3.5 yuan per share [19][20]